Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Revive Therapeutics ( (TSE:RVV) ) has issued an update.
Revive Therapeutics has acquired the molecular hydrogen program from DiagnaMed Holdings, expanding its pipeline to include potential treatments for neurological and mental health disorders such as ALS, Dementia, and Depression. This acquisition, which includes a provisional patent application and an Orphan Drug Designation by the FDA for ALS, positions Revive to accelerate its development programs, offering hope to patients with limited treatment options.
More about Revive Therapeutics
Revive Therapeutics is a life sciences company that focuses on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures. The company prioritizes drug development efforts to leverage regulatory incentives from the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Revive is currently exploring treatments for nerve agent exposure, long COVID, and advancing the development of Psilocybin and molecular hydrogen therapeutics.
YTD Price Performance: 50.0%
Average Trading Volume: 339,155
Technical Sentiment Signal: Buy
Current Market Cap: C$8.37M
Find detailed analytics on RVV stock on TipRanks’ Stock Analysis page.